Remote Supervision to Decrease Hospitalization Rate

The RESULT trial is a prospective, single-center, randomized, open label, parallel study. All consecutive patients with symptomatic HF and reduced ejection fraction (≤ 35%) with ICDs or CRT-Ds implanted accordingly to current ESC practice guidelines will be prospectively randomized in a 1:1 fashion to either a traditional or an RM-based follow-up model. Six hundred patients will be enrolled. The inclusion and exclusion criteria are shown in Table 1. The clinical status of patients will be estimated using the composite endpoint of all-cause death and hospitalization due to cardiovascular reasons. The study protocol has been approved by a local ethics committee and complies with the Declaration of Helsinki. A written informed consent will be obtained from all study participants. Primary endpoint The primary endpoint of the trial will be a composite of all-cause death or hospitalization due to cardiovascular reasons. Hospitalization for cardiovascular reasons should consist of:

• Hospitalization due to progression of heart failure.
• Hospitalization due to persistent arrhythmia (AF, VT).
• Hospitalization due to embolic episode.
• Hospitalization due to acute coronary syndrome. Every patient will be followed for at least 12 months after randomization. Assessment of hospitalization events for cardiovascular reasons will be performed according to a recently published consensus [13]. The final classification of hospital admissions due to cardiovascular reasons will be made by a blinded endpoints committee. The primary technical endpoint is to construct and evaluate a unified and integrated platform for data collected from RM devices manufactured by different companies: Carelink™ (Medtronic®, Minneapolis, MN, USA), Merlin™ (Saint Jude Medical®, St. Paul, MN, USA) and Home Monitoring™ (Biotronik®, Berlin, Germany). Secondary endpoints Both elements combined in the primary endpoint will be analyzed separately to estimate their relative impact on the primary endpoint.

The secondary endpoints include the following:

• All-cause death.
• Hospitalization due to cardiovascular reasons.
• Time to medical intervention in case of relevant incidents (arrhythmic, device malfunction, signs of HF decompensation).
• Average number of visits to an outpatient clinic (scheduled and unscheduled) per patient.
• Time to first unscheduled visit in an outpatient clinic.
• Incidence of inappropriate ICD shocks.
• Proportion of visits to outpatient clinics with relevant findings (necessity of changes of device programming or pharmacological therapy, rehospitalization, interventions, invasive procedures).
• Assessment of quality of life of living study participants according to the Minnesota Quality of Life Questionnaire.
• Cost-effectiveness, defined as the cost of hospitalizations and/or scheduled and unscheduled visits in both groups.

All consecutive patients after implantation of an ICD or CRT-D manufactured by St.

Jude Medical, Biotronik or Medtronic will undergo an initial evaluation. Patients who have given informed consent and who fulfill the inclusion/exclusion criteria will be screened. Randomization to the RM or control group will be conducted within 30 days after ICD or CRT-D implantation and after the final programming of sensing and stimulation parameters. The time of observation in both groups will be 12 months after randomization. In the RM group only, one follow-up visit will be planned 12 months after being enrolled in the trial. In the control group, follow-up visits will be planned at 3, 6, 9 and 12 months after being enrolled in the trial, according to the normal procedure in our center. Unscheduled visits in both groups can be initiated either by the patient or by the supervising staff. The limits of therapeutic intervention will be individualized depending on the clinical situation according to valid ESC guidelines and will include the following: modification of device settings, modification of pharmacotherapy and performing necessary invasive diagnostic and therapeutic procedures.

Inclusion criteria

• Age 18-80 years
• EF≤35% prior to implantation
• Period up to 30 days after implantation (ICD/CRT-D) according to ESC guidelines
• Agreement for telemetric supervision
• Informed consent for clinical trial.

Exclusion criteria

• Existence of factors that may cause risk for lack of cooperation in trial regimen (distant residence, mental illness, lack of skills in operating simple electronic devices).
• unavailability of mobile network service in the place of residence/stay.
• Device implanted during intravenous administration of inotropic agents.